Physician profile
Edwin Js Lee
NPI 1972921047
$2,326.17
in general payments reported to CMS, 2019-2025
17 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.24 · 2022: $442 · 2023: $355 · 2024: $598 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,180.08 | 2021-2025 | |
| Inspire Medical Systems, INC. | $248.82 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $170.55 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.84 | 2022-2024 | Xifaxan, Trulance |
| Celgene Corporation | $99.18 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $81.76 | 2024-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $74.13 | 2023-2025 | Rebyota |
| Alnylam Pharmaceuticals INC. | $58.46 | 2024-2025 | Givlaari |
| Janssen Biotech, INC. | $54.65 | 2025 | Tremfya |
| Pfizer INC. | $49.40 | 2024-2025 | |
| Gilead Sciences, INC. | $42.97 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $42.28 | 2021-2023 | Dificid |
| Novo Nordisk INC | $37.17 | 2025 | Wegovy |
| Celltrion USA INC. | $27.60 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $17.34 | 2024 | Voquezna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $16.85 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.09 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.